I
10.60
0.40 (3.92%)
| Penutupan Terdahulu | 10.20 |
| Buka | 10.04 |
| Jumlah Dagangan | 511,216 |
| Purata Dagangan (3B) | 873,126 |
| Modal Pasaran | 1,288,576,640 |
| Harga / Jualan (P/S) | 12.45 |
| Harga / Buku (P/B) | 2.55 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 17 Nov 2025 |
| Margin Keuntungan | -15.54% |
| Margin Operasi (TTM) | -190.37% |
| EPS Cair (TTM) | -0.200 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -38.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.43% |
| Nisbah Semasa (MRQ) | 10.28 |
| Aliran Tunai Operasi (OCF TTM) | -159.63 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -117.80 M |
| Pulangan Atas Aset (ROA TTM) | -5.84% |
| Pulangan Atas Ekuiti (ROE TTM) | -4.78% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Immatics N.V. | Menaik | Menaik |
AISkor Stockmoo
-0.1
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 2.0 |
| Purata | -0.13 |
|
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 22.85% |
| % Dimiliki oleh Institusi | 79.42% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 25.00 (Chardan Capital, 135.85%) | Beli |
| Median | 23.00 (116.98%) | |
| Rendah | 19.00 (Guggenheim, 79.25%) | Beli |
| Purata | 22.33 (110.66%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 10.42 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Chardan Capital | 24 Nov 2025 | 25.00 (135.85%) | Beli | 10.60 |
| Mizuho | 19 Nov 2025 | 23.00 (116.98%) | Beli | 10.33 |
| Guggenheim | 18 Nov 2025 | 19.00 (79.25%) | Beli | 10.32 |
| 18 Sep 2025 | 16.00 (50.94%) | Beli | 6.61 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |